Targeting JAK Signalling in the Treatment of Vitiligo

Time: 9:50 am
day: Day Two


  • Overview of vitiligo pathogenesis, psychosocial comorbidities and unmet medical need
  • Discuss vitiligo competitive landscape, current challenges in conducting vitiligo clinical trials and regulatory path
  • Demonstrate efficacy and safety of ruxolitinib (JAK inhibitor) cream and discuss subgroup analysis based on patient demographics and clinical characteristics from a phase 2 vitiligo clinical trial